No Data
No Data
Phio Pharma To Present Update On Proprietary INTASYL Sirna Technology And Progress On On-Going Clinical Trial With Lead Compound PH-762 For Treatment Of Skin Cancers
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference
Express News | Phio Pharma Q1 EPS $(0.47) Down From $(0.41) YoY
Phio Pharmaceuticals | 10-Q: Q1 2025 Earnings Report
Phio Pharmaceuticals | 8-K: Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial